For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...

The biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments while offering investors the possibility of significant returns. However, investing in these companies requires a nuanced understanding of their pipelines, regulatory landscapes and market dynamics. Identifying biotech stocks to double your money is certainly no easy feat. But looking at companies with late-stage drug approval potential and market dominance in their respective fields is a great start. While b ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth S ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are th ...

United Therapeutics‘ (UTHR) first-quarter 2024 earnings of $6.17 per share beat the Zacks Consensus Estimate of $5.63. Earnings rose 27% year over year on the back of higher product sales.Revenues were $677.7 million, which beat the Zacks Consensus Estimate of $628 million. Revenues rose 34% year over year, driven by meaningful growth of all key products — Tyvaso, Orenitram, Remodulin and Unituxin.Quarter in DetailUnited Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Remoduli ...

财务数据和关键指标变化 - 公司第一季度收入达到创纪录的6.78亿美元,同比增长34% [22] - Tyvaso收入为3.73亿美元,同比增长56%,主要由于Tyvaso DPI销售增加、年度价格上涨以及通胀减免法案实施后商业使用增加 [23][26] - Orenitram收入首次超过1亿美元,达到1.06亿美元,同比增长20%,主要由于商业使用增加、价格上涨以及季节性因素 [30] - Remodulin收入为1.28亿美元,同比增长5%,保持强劲势头 [31] - Unituxin收入为5800万美元,创新高,同比增长19% [34] 各条业务线数据和关键指标变化 - Tyvaso DPI和Tyvaso雾化器销量合计为公司最大产品,仍是美国使用最广泛的前列腺素类药物 [23] - Tyvaso DPI处方量和患者启动量均呈增长趋势,第一季度总体处方量增加10%-15% [24][25] - Orenitram商业使用增加,主要受益于通胀减免法案实施 [30] - Remodulin仍是美国使用最广泛的静脉和皮下前列腺素类药物,Remunity泵是新皮下患者的唯一选择 [32] - Unituxin美国销售增长21%,主要由于价格和销量双双上涨 [34] 各个市场数据和关键指标变化 - 公司产品在肺动脉高压(PAH)和间质性肺疾病相关肺高压(PH-ILD)市场保持领先地位 [35] - 预计随着通胀减免法案实施,Tyvaso DPI和Orenitram的商业使用将持续增加 [26][30] 公司战略和发展方向及行业竞争 - 公司有多款最佳类别产品,正在开展多项III期临床试验,未来有望帮助两倍于现有患者人数 [15] - 公司在器官制造领域取得重大进展,成功帮助更多肺部移植、开始肝脏辅助产品临床试验,并成功移植首例人工胸腺肾 [16] - 公司认为Tyvaso DPI凭借独特的单次吸入设计、更高的给药效率等优势,将能够有效应对未来同类产品竞争 [27][28][29] - 公司认为sotatercept是与现有前列腺素类药物互补的产品,不会取代前列腺素类药物的使用 [50][51] 管理层对经营环境和未来前景的评论 - 公司对未来前景充满信心,认为股票目前被严重低估,此次10亿美元股票回购是最佳投资回报 [17] - 公司将继续优先投资于管线和业务发展,同时也会适当回馈股东 [9] - 公司预计Tyvaso在PAH和PH-ILD适应症的销售将持续增长,并有望在特发性肺纤维化适应症获批后进一步扩大 [19] - 公司认为Remodulin和Orenitram等核心产品将保持良好增长势头 [18][32] 问答环节重要的提问和回答 问题1 **Terence Flynn 提问** - 询问Tyvaso在ILD市场的处方覆盖面和Remodulin患者使用Remunity泵的比例 [38] **Michael Benkowitz 回答** - Tyvaso在ILD市场的处方覆盖面和深度都在持续提升,过去15个月新增ILD医生处方量增加50%,三次以上处方医生增加30% [40][41] - Remodulin患者中绝大部分已转移到Remunity泵,预计到年底剩余少量患者也将完成转移 [42] 问题2 **Roanna Ruiz 提问** - 询问公司对sotatercept上市后与Tyvaso联合使用的预期 [45] **Michael Benkowitz 回答** - 公司认为sotatercept是与现有前列腺素类药物互补的产品,不会取代前列腺素类药物的使用,预计大部分患者会继续联合使用 [50][51] 问题3 **Ash Verma 提问** - 询问公司在基因修饰猪的选择和数量方面的考虑,与竞争对手的方法有何不同 [54] **Leigh Peterson 回答** - 公司正在开发10基因修饰猪的肾脏和心脏,同时也在研究单基因修饰的"胸腺肾",两种方法各有优势,公司将通过临床试验验证其安全性和有效性 [57][64][65]

United Therapeutics (UTHR) reported $677.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 33.7%. EPS of $6.17 for the same period compares to $4.86 a year ago.The reported revenue represents a surprise of +7.96% over the Zacks Consensus Estimate of $627.72 million. With the consensus EPS estimate being $5.63, the EPS surprise was +9.59%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...